动态反流监测指导胃食管反流症状患者停用质子泵抑制剂:一项临床试验
这项双盲临床试验在2个中心历时3年纳入128例有烧心、反流和/或胸痛且质子泵抑制剂(PPI)应答不佳的成人,最终100例符合标准。结果显示34%成功停用PPI,酸暴露时间(AET)>4.0%的天数是停用PPI的最强预测因子(OR 1.82,P<.001),停药组症状负担降幅大于继续用药组(RESQ-eD -43.7% vs -5.3%,P=.04)。
要点
- AET>4.0%天数越多,越可能成功停用PPI(OR 1.82,P<.001)。
- 0天AET>4.0%者停用PPI的比值是4天者的10倍。
- 停药组症状负担降幅大于继续用药组(-43.7% vs -5.3%,P=.04)。
核心结论
- 在有典型反流症状、PPI应答不佳且无严重食管炎的患者中,反流监测显示的酸暴露可预测停用PPI后症状不加重。
- 提前在停用抑酸治疗期间行反流监测可减少不必要的PPI使用并指导个体化管理。
研究设计与样本
- 双盲临床试验,历时3年,在2个中心开展。
- 入选标准为有烧心、反流和/或胸痛等烦人食管症状且PPI应答不佳的成人。
- 共入组128例,其中100例符合纳入标准(平均年龄48.6岁;男性41例)。
- 参与者接受长时间无线反流监测(停用PPI≥7天)及为期3周的PPI停用干预。
- 主要结局为PPI停用的耐受性(停用或恢复PPI)。
主要发现
- 34例参与者(34%)停用了PPI。
- 停用PPI的最强预测因子是AET>4.0%的天数(比值比1.82;P<.001)。
- AET>4.0%为0天的参与者停用PPI的比值是AET>4.0%为4天者的10倍。
- 停药组症状负担降幅大于继续用药组(RESQ-eD,-43.7% vs -5.3%;P=.04)。
关键数值与推荐
- AET>4.0%的天数:比值比1.82(P<.001),为停用PPI的最强预测因子。
- AET>4.0%为0天者停用PPI的比值是4天者的10倍。
- 症状负担变化:停药组-43.7% vs 继续用药组-5.3%(P=.04)。
临床怎么用
- 在有典型反流症状、PPI应答不佳且无严重食管炎的患者中,可考虑在停用抑酸治疗期间行反流监测以预测停用PPI后症状是否加重。
- 提前在停用抑酸治疗期间行反流监测可减少不必要的PPI使用并指导个体化管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Proton pump inhibitor (PPI) therapy fails to provide adequate symptom control in up to 50% of patients with gastroesophageal reflux symptoms. Although a proportion do not require ongoing PPI therapy, a diagnostic approach to identify candidates appropriate for PPI cessation is not available. This study aimed to examine the clinical utility of prolonged wireless reflux monitoring to predict the ability to discontinue PPIs. METHODS: This double-blinded clinical trial performed over 3 years at 2 centers enrolled adults with troublesome esophageal symptoms of heartburn, regurgitation, and/or chest pain and inadequate PPI response. Participants underwent prolonged wireless reflux monitoring (off PPIs for ≥7 days) and a 3-week PPI cessation intervention. Primary outcome was tolerance of PPI cessation (discontinued or resumed PPIs). Symptom burden was quantified using the Reflux Symptom Questionnaire electronic Diary (RESQ-eD). RESULTS: Of 128 enrolled, 100 participants met inclusion criteria (mean age, 48.6 years; 41 men). Thirty-four participants (34%) discontinued PPIs. The strongest predictor of PPI discontinuation was number of days with acid exposure time (AET) > 4.0% (odds ratio, 1.82; P < .001). Participants with 0 days of AET > 4.0% had a 10 times increased odds of discontinuing PPI than participants with 4 days of AET > 4.0%. Reduction in symptom burden was greater among the discontinued versus resumed PPI group (RESQ-eD, -43.7% vs -5.3%; P = .04). CONCLUSIONS: Among patients with typical reflux symptoms, inadequate PPI response, and absence of severe esophagitis, acid exposure on reflux monitoring predicted the ability to discontinue PPIs without symptom escalation. Upfront reflux monitoring off acid suppression can limit unnecessary PPI use and guide personalized management. (ClinicalTrials.gov, Number: NCT03202537).
引用
- Yadlapati R, Masihi M, Gyawali CP, et al. Ambulatory Reflux Monitoring Guides Proton Pump Inhibitor Discontinuation in Patients With Gastroesophageal Reflux Symptoms: A Clinical Trial. Gastroenterology. 2020. PMID: 32949568. doi:10.1053/j.gastro.2020.09.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。